human normal immunoglobulin




Zuellig Pharma
Concise Prescribing Info
Human IgG ≥98%
Listed in Dosage.
Dosage/Direction for Use
IV infusion Replacement therapy in primary immunodeficiency Initially 0.4-0.8 g/kg body wt. Maintenance: 0.2-0.8 g/kg body wt every 2-4 wk to obtain IgG trough level of at least 4-6 g/L. Replacement therapy in secondary immunodeficiency due to myeloma or chronic lymphocytic leukaemia 0.2-0.4 g/kg body wt every 3-4 wk to obtain IgG trough level of at least 4-6 g/L. Replacement therapy in childn w/ congenital AIDS & recurrent infections 0.2-0.4 g/kg body wt every 3-4 wk. Idiopathic thrombocytopenic purpura in childn or adult at high risk of bleeding or pre-op to correct platelet count 0.8-1 g/kg body wt on day 1, may repeat once w/in 3 days or 0.4 g/kg body wt daily for 2-5 days. May repeat if relapse occurs. Guillain-Barré syndrome 0.4 g/kg body wt/day for 3-7 days. Kawasaki disease 2 g/kg body wt as a single dose or 1.6-2 g/kg body wt in divided doses over 2-5 days. Concomitant w/ acetylsalicylic acid. Allogeneic bone marrow transplantation: Treatment of infections & prophylaxis of graft versus host disease 0.5 g/kg body wt/wk starting 7 days before & up to 3 mth after transplantation. Persistent lack of Ab production 0.5 g/kg body wt/mth until Ab level returns to normal.
Hypersensitivity. IgA deficiency.
Special Precautions
Obese patients, risk factors for thrombotic events eg, atherosclerosis, multiple CV risk factors, advanced age, impaired cardiac output, HTN, DM, vascular disease or thrombotic episodes, acquired or inherited thrombophilic disorders, hypercoagulable disorders, prolonged periods of immobilisation, severe hypovolemia, diseases which increase blood viscosity, renal insufficiency, sepsis or paraproteinemia. Discontinue in case of renal impairment. Noncardiogenic pulmonary edema; hemolytic anemia. Monitor urine output & serum creatinine levels. Adequate hydration. Pregnancy, lactation.
Adverse Reactions
Chills, fever, vomiting, allergic reactions, nausea, arthralgia, low BP, moderate low back pain, bronchitis, nasopharyngitis, dizziness, migraine, vertigo, tachycardia, HTN, cough, rhinorrhoea, diarrhoea, nausea, pruritus, rash, urticaria, myalgia, pain in extremity, fatigue, flu-like illness, infusion site pain/swelling, rigors, increased body temp. Headache & flushing (due to rate of infusion).
Drug Interactions
Live attenuated virus vaccines, loop diuretics.
ATC Classification
J06BA02 - immunoglobulins, normal human, for intravascular adm. ; Belongs to the class of normal human immunoglobulins. Used in passive immunizations.
Kiovig infusion 2.5 g/25 mL
(vial) 1's
Kiovig infusion 5 g/50 mL
(vial) 1's
Kiovig infusion 10 g/100 mL
(vial) 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in